Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial.
暂无分享,去创建一个
Ian J Constable | Steven D Schwartz | I. Constable | E. Rakoczy | M. Blumenkranz | A. Magno | M. Degli-Esposti | S. Schwartz | C. Lai | M. French | Mark S Blumenkranz | Chooi-May Lai | Aaron L Magno | Martyn A French | Samuel B Barone | Mariapia A Degli-Esposti | Elizabeth P Rakoczy | S. Barone
[1] Jean Bennett,et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. , 2005, Diabetes.
[2] A. Ho,et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. , 2015, American journal of ophthalmology.
[3] Ian J Constable,et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial , 2015, The Lancet.
[4] F. Gueyffier,et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. , 2014, JAMA ophthalmology.
[5] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[6] G. Veres,et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] C. Costagliola,et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview , 2014, Expert opinion on drug safety.
[8] Laura G. Qualls,et al. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. , 2014, American journal of ophthalmology.
[9] C. Regillo,et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.
[10] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[11] R. Guymer,et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. , 2013, Ophthalmology.
[12] C. Costagliola,et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration , 2012, Expert opinion on biological therapy.
[13] W. Freeman,et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.
[14] Usha Chakravarthy,et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.
[15] Laura G. Qualls,et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. , 2012, American journal of ophthalmology-glaucoma.
[16] I. Constable,et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] Benita J. O’Colmain,et al. Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.
[18] C. Regillo,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.
[19] P. Rakoczy,et al. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy , 2002, Gene Therapy.
[20] Ivana K. Kim,et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] J. Vander,et al. Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .
[22] Usha Chakravarthy,et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. , 2014, The Cochrane database of systematic reviews.
[23] I J Constable,et al. Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates , 2011, Gene Therapy.
[24] Laura G. Qualls,et al. COSTS OF NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMONG MEDICARE BENEFICIARIES, 2004–2008 , 2013, Retina.
[25] Usha Chakravarthy,et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial , 2013, The Lancet.
[26] E. Rakoczy,et al. rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. , 2009, Investigative Ophthalmology and Visual Science.
[27] J. Nowak,et al. Age-related macular degeneration (AMD): pathogenesis and therapy. , 2006, Pharmacological reports : PR.
[28] Mark Michels,et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.
[29] P. Mitchell,et al. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? , 2011, American journal of ophthalmology.
[30] J. Vander. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007 , 2012 .
[31] Takuhiro Yamaguchi,et al. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. , 2014, Ophthalmology.
[32] J. Vander. A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Clinical and Economic Impact , 2011 .
[33] U. Chakravarthy,et al. Systemic safety of anti-VEGF drugs: a commentary , 2015, Expert opinion on drug safety.
[34] J. Bennett,et al. Novel AAV serotypes for improved ocular gene transfer , 2008, The journal of gene medicine.
[35] P. Rosenfeld,et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. , 2011, American journal of ophthalmology.
[36] M. Tolentino. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. , 2011, Survey of ophthalmology.
[37] R. Kendall,et al. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[38] Wayne T. A. Enanoria,et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. , 2015, American journal of ophthalmology.